Haemonetics Corporation (HAE) P/E Ratio History
UndervaluedTrading at 36.2x vs 5Y avg 44.6x · 50th percentile · Below historical baseline · Data 1992–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Haemonetics Corporation (HAE) trades at a price-to-earnings ratio of 36.2x, with a stock price of $74.17 and trailing twelve-month earnings per share of $2.11.
The current P/E is 19% below its 5-year average of 44.6x. Over the past five years, HAE's P/E has ranged from a low of 14.1x to a high of 122.6x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, HAE trades at a 64% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 6.29 (P/E divided by -38% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, HAE commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HAE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HAE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HAE P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $17B | 30.5 | - | -25% | |
| $3B | 31.5 | 7.15 | -15% | |
| $52B | 24.7 | 1.49 | -1% | |
| $144B | 51.7 | 2.37 | +23% | |
| $11B | 20.2Lowest | 0.65Best | +423%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HAE Historical P/E Data (1992–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q4 | Mar 28 2026 | $54.04 | $2.02 | 26.8x | -64% |
| FY2026 Q3 | Dec 27 2025 | $80.28 | $3.63 | 22.1x | -70% |
| FY2026 Q2 | Sep 27 2025 | $48.17 | $3.42 | 14.1x | -81% |
| FY2026 Q1 | Jun 28 2025 | $73.80 | $3.27 | 22.6x | -69% |
| FY2025 Q4 | Mar 31 2025 | $63.55 | $3.31 | 19.2x | -74% |
| FY2025 Q3 | Dec 28 2024 | $77.57 | $2.54 | 30.5x | -59% |
| FY2025 Q2 | Sep 28 2024 | $79.80 | $2.41 | 33.1x | -55% |
| FY2025 Q1 | Jun 29 2024 | $82.73 | $2.23 | 37.1x | -50% |
| FY2024 Q4 | Mar 31 2024 | $85.35 | $2.29 | 37.3x | -49% |
| FY2024 Q3 | Dec 30 2023 | $85.51 | $2.46 | 34.8x | -53% |
| FY2024 Q2 | Sep 30 2023 | $89.58 | $2.49 | 36.0x | -51% |
| FY2024 Q1 | Jul 01 2023 | $85.14 | $2.65 | 32.1x | -56% |
| FY2023 Q4 | Mar 31 2023 | $82.75 | $2.23 | 37.1x | -50% |
| FY2023 Q3 | Dec 31 2022 | $78.65 | $1.85 | 42.5x | -42% |
| FY2023 Q2 | Oct 01 2022 | $74.03 | $1.66 | 44.6x | -40% |
| FY2023 Q1 | Jul 02 2022 | $67.32 | $1.31 | 51.4x | -30% |
| FY2022 Q4 | - | $63.22 | $0.84 | 75.0x | +2% |
| FY2022 Q3 | Jan 01 2022 | $53.04 | $0.43 | 122.6x | +66% |
| FY2022 Q2 | Oct 02 2021 | $72.00 | $0.60 | 119.5x | +62% |
| FY2022 Q1 | Jul 03 2021 | $66.60 | $1.25 | 53.2x | -28% |
| FY2021 Q4 | Mar 31 2021 | $111.01 | $1.55 | 71.6x | -3% |
| FY2021 Q3 | Dec 26 2020 | $118.75 | $2.11 | 56.3x | -24% |
| FY2021 Q2 | Sep 26 2020 | $87.12 | $2.07 | 42.1x | -43% |
| FY2021 Q1 | Jun 27 2020 | $87.60 | $1.85 | 47.4x | -36% |
| FY2020 Q4 | - | $99.66 | $1.47 | 67.8x | -8% |
| FY2020 Q3 | Dec 28 2019 | $115.94 | $1.53 | 75.8x | +3% |
| FY2020 Q2 | Sep 28 2019 | $124.18 | $1.30 | 95.5x | +29% |
| FY2020 Q1 | Jun 29 2019 | $120.34 | $0.93 | 129.4x | +75% |
| FY2019 Q4 | Mar 31 2019 | $87.48 | $1.05 | 83.6x | +13% |
| FY2019 Q3 | Dec 29 2018 | $95.73 | $0.87 | 110.6x | +50% |
| FY2019 Q2 | Sep 29 2018 | $114.58 | $0.40 | 289.4x | +292% |
| FY2019 Q1 | Jun 30 2018 | $89.68 | $0.43 | 210.6x | +185% |
| FY2018 Q4 | Mar 31 2018 | $73.16 | $0.86 | 85.1x | +15% |
| FY2018 Q2 | Sep 30 2017 | $44.87 | $0.08 | 560.9x | +660% |
| FY2018 Q1 | Jul 01 2017 | $39.49 | $0.08 | 493.6x | +569% |
| FY2017 Q3 | Dec 31 2016 | $40.20 | $0.31 | 129.7x | +76% |
| FY2016 Q2 | Sep 26 2015 | $34.35 | $0.50 | 69.0x | -7% |
| FY2016 Q1 | Jun 27 2015 | $42.00 | $0.39 | 108.2x | +47% |
| FY2015 Q4 | - | $44.92 | $0.32 | 139.2x | +89% |
| FY2015 Q3 | Dec 27 2014 | $38.41 | $0.57 | 67.4x | -9% |
| FY2015 Q2 | Sep 27 2014 | $34.62 | $0.57 | 60.8x | -18% |
| FY2015 Q1 | Jun 28 2014 | $35.62 | $0.75 | 47.5x | -36% |
| FY2014 Q4 | Mar 31 2014 | $32.59 | $0.67 | 48.6x | -34% |
| FY2014 Q3 | Dec 28 2013 | $43.02 | $0.72 | 59.8x | -19% |
| FY2014 Q2 | Sep 28 2013 | $39.95 | $0.60 | 66.6x | -10% |
| FY2014 Q1 | Jun 29 2013 | $41.35 | $0.41 | 100.9x | +37% |
| FY2013 Q4 | Mar 31 2013 | $41.66 | $0.75 | 55.5x | -25% |
| FY2013 Q3 | Dec 29 2012 | $39.98 | $0.86 | 46.5x | -37% |
| FY2013 Q2 | Sep 29 2012 | $40.10 | $1.03 | 38.9x | -47% |
| FY2013 Q1 | Jun 30 2012 | $37.05 | $1.17 | 31.7x | -57% |
| FY2012 Q4 | Mar 31 2012 | $34.84 | $1.31 | 26.6x | -64% |
| FY2012 Q3 | Dec 31 2011 | $30.61 | $1.36 | 22.5x | -69% |
| FY2012 Q2 | Oct 01 2011 | $29.24 | $1.39 | 21.0x | -71% |
| FY2012 Q1 | Jul 02 2011 | $32.90 | $1.55 | 21.2x | -71% |
| FY2011 Q4 | - | $32.77 | $1.57 | 20.9x | -72% |
| FY2011 Q3 | Jan 01 2011 | $31.59 | $1.25 | 25.3x | -66% |
| FY2011 Q2 | Oct 02 2010 | $29.29 | $1.22 | 24.1x | -67% |
| FY2011 Q1 | Jul 03 2010 | $27.76 | $1.14 | 24.4x | -67% |
| FY2010 Q4 | Mar 31 2010 | $28.57 | $1.14 | 25.1x | -66% |
| FY2010 Q3 | Dec 26 2009 | $27.86 | $1.33 | 21.0x | -72% |
| FY2010 Q2 | Sep 26 2009 | $27.89 | $1.28 | 21.8x | -70% |
| FY2010 Q1 | Jun 27 2009 | $28.59 | $1.21 | 23.6x | -68% |
| FY2009 Q4 | - | $27.54 | $1.13 | 24.4x | -67% |
| FY2009 Q3 | Dec 27 2008 | $27.61 | $1.12 | 24.6x | -67% |
| FY2009 Q2 | Sep 27 2008 | $30.45 | $1.08 | 28.2x | -62% |
| FY2009 Q1 | Jun 28 2008 | $28.88 | $1.01 | 28.6x | -61% |
| FY2008 Q4 | Mar 31 2008 | $29.79 | $0.97 | 30.7x | -58% |
| FY2008 Q3 | Dec 29 2007 | $31.20 | $1.08 | 28.9x | -61% |
| FY2008 Q2 | Sep 29 2007 | $24.71 | $1.12 | 22.1x | -70% |
| FY2008 Q1 | Jun 30 2007 | $26.30 | $0.94 | 28.1x | -62% |
| FY2007 Q4 | Mar 31 2007 | $23.38 | $0.91 | 25.8x | -65% |
| FY2007 Q3 | Dec 30 2006 | $22.51 | $0.84 | 26.6x | -64% |
| FY2007 Q2 | Sep 30 2006 | $23.40 | $1.04 | 22.4x | -70% |
| FY2007 Q1 | Jul 01 2006 | $23.25 | $1.22 | 19.1x | -74% |
| FY2006 Q4 | Mar 31 2006 | $25.39 | $1.26 | 20.1x | -73% |
| FY2006 Q3 | Dec 31 2005 | $24.43 | $1.13 | 21.6x | -71% |
| FY2006 Q2 | Oct 01 2005 | $23.77 | $0.83 | 28.6x | -61% |
| FY2006 Q1 | Jul 02 2005 | $20.05 | $0.80 | 25.1x | -66% |
| FY2005 Q4 | - | $21.08 | $0.75 | 28.1x | -62% |
| FY2005 Q3 | Jan 01 2005 | $18.11 | $0.76 | 23.8x | -68% |
| FY2005 Q2 | Oct 02 2004 | $16.55 | $0.74 | 22.4x | -70% |
| FY2005 Q1 | Jul 03 2004 | $14.71 | $0.69 | 21.3x | -71% |
| FY2004 Q4 | Mar 31 2004 | $15.72 | $0.61 | 25.8x | -65% |
| FY2004 Q3 | Dec 27 2003 | $11.88 | $0.51 | 23.2x | -69% |
| FY2004 Q2 | Sep 27 2003 | $11.84 | $0.53 | 22.2x | -70% |
| FY2004 Q1 | Jun 28 2003 | $9.11 | $0.55 | 16.5x | -78% |
| FY2003 Q4 | Mar 31 2003 | $10.93 | $0.57 | 19.1x | -74% |
| FY2003 Q3 | Dec 28 2002 | $11.00 | $0.62 | 17.7x | -76% |
| FY2003 Q2 | Sep 28 2002 | $11.77 | $0.46 | 25.9x | -65% |
| FY2003 Q1 | Jun 29 2002 | $14.60 | $0.51 | 28.9x | -61% |
| FY2002 Q4 | Mar 31 2002 | $15.87 | $0.56 | 28.1x | -62% |
| FY2002 Q3 | Dec 29 2001 | $17.10 | $0.56 | 30.3x | -59% |
| FY2002 Q2 | Sep 29 2001 | $17.30 | $0.69 | 25.1x | -66% |
| FY2002 Q1 | Jun 30 2001 | $15.25 | $0.20 | 76.3x | +3% |
| FY2001 Q4 | Mar 31 2001 | $16.55 | $0.13 | 127.3x | +73% |
| FY2001 Q3 | Dec 30 2000 | $15.44 | $0.01 | 3027.0x | +4003% |
| FY2001 Q1 | Jul 01 2000 | $10.50 | $0.38 | 28.0x | -62% |
| FY2000 Q4 | Mar 31 2000 | $11.25 | $0.37 | 30.8x | -58% |
| FY2000 Q3 | Dec 25 1999 | $11.50 | $0.46 | 25.0x | -66% |
| FY2000 Q2 | Oct 02 1999 | $9.84 | $0.42 | 23.4x | -68% |
| FY2000 Q1 | Jul 03 1999 | $9.66 | $0.41 | 23.6x | -68% |
| FY1999 Q4 | Mar 31 1999 | $7.84 | $0.40 | 19.9x | -73% |
| FY1998 Q3 | Dec 27 1997 | $6.91 | $0.13 | 55.3x | -25% |
| FY1998 Q2 | Sep 27 1997 | $9.41 | $0.47 | 19.8x | -73% |
| FY1998 Q1 | Jun 28 1997 | $9.66 | $0.56 | 17.2x | -77% |
| FY1997 Q4 | Mar 31 1997 | $8.88 | $0.61 | 14.5x | -80% |
| FY1997 Q3 | Dec 28 1996 | $9.38 | $0.62 | 15.1x | -80% |
| FY1997 Q2 | Sep 28 1996 | $10.56 | $0.65 | 16.3x | -78% |
| FY1997 Q1 | Jun 29 1996 | $9.13 | $0.66 | 13.8x | -81% |
| FY1996 Q4 | Mar 31 1996 | $8.31 | $0.65 | 12.8x | -83% |
| FY1996 Q3 | Dec 31 1995 | $8.88 | $0.64 | 13.9x | -81% |
| FY1996 Q2 | Sep 30 1995 | $11.50 | $0.63 | 18.3x | -75% |
| FY1996 Q1 | Jun 30 1995 | $9.63 | $0.61 | 15.8x | -79% |
| FY1995 Q4 | Mar 31 1995 | $7.25 | $0.59 | 12.3x | -83% |
| FY1995 Q3 | Dec 31 1994 | $8.63 | $0.59 | 14.6x | -80% |
| FY1995 Q2 | Sep 30 1994 | $9.06 | $0.58 | 15.6x | -79% |
| FY1995 Q1 | - | $9.06 | $0.57 | 15.9x | -78% |
| FY1994 Q4 | - | $9.94 | $0.55 | 18.1x | -76% |
| FY1994 Q3 | Dec 31 1993 | $13.88 | $0.52 | 26.7x | -64% |
| FY1994 Q2 | - | $12.06 | $0.50 | 24.1x | -67% |
| FY1994 Q1 | Jun 30 1993 | $12.44 | $0.47 | 26.5x | -64% |
| FY1993 Q4 | Mar 31 1993 | $12.00 | $0.45 | 27.0x | -63% |
| FY1993 Q3 | - | $13.09 | $0.42 | 31.0x | -58% |
| FY1993 Q2 | Sep 30 1992 | $9.38 | $0.38 | 24.5x | -67% |
| FY1993 Q1 | - | $8.00 | $0.35 | 23.0x | -69% |
| FY1992 Q4 | - | $6.34 | $0.32 | 20.0x | -73% |
Average P/E for displayed period: 73.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
34+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
What is HAE's P/E ratio?
Haemonetics Corporation (HAE) trailing twelve-month P/E ratio is 36.2x, based on TTM diluted EPS of $2.11. The 5-year average P/E is 44.6x and the historical range spans 14.1x to 122.6x.
Is HAE stock overvalued or undervalued?
HAE trades at 36.2x P/E, near its 5-year average of 44.6x. The 50th percentile ranking within the 14.1x–122.6x historical range places valuation within normal bounds.
Is HAE stock expensive?
HAE is fairly valued relative to its own history. The current P/E of 36.2x is near the 5-year average of 44.6x (50th percentile of historical range).
What is HAE's historical P/E range?
Over the past 5 years, HAE's P/E ratio has ranged from 14.1x to 122.6x, with a median of 37.1x and an average of 44.6x. The current P/E of 36.2x places the stock at the 50th percentile of this range. Full historical data spans 1992–2026.
How does HAE's P/E compare to the S&P 500?
HAE trades at 36.2x P/E versus the S&P 500 median of 24.4x. The 48% premium to the market typically reflects higher expected earnings growth or quality.
How does HAE's valuation compare to Healthcare peers?
Haemonetics Corporation P/E of 36.2x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HAE's PEG ratio?
HAE PEG ratio is 6.29, based on a P/E of 36.2x and EPS growth of -38.1%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is HAE's earnings yield?
HAE earnings yield is 2.76%, the inverse of its 36.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.